AUB ScholarWorks

A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC)

Show simple item record

dc.contributor.author Shamseddine A.
dc.contributor.author Khalifeh M.
dc.contributor.author Chehal A.
dc.contributor.author Saliba T.
dc.contributor.author Mourad Y.A.
dc.contributor.author Taher A.
dc.contributor.author Jalloul R.
dc.contributor.author Bitar N.
dc.contributor.author Dandashi A.
dc.contributor.author Abbas J.
dc.contributor.author Geara F.B.
dc.contributor.editor
dc.date Aug-2005
dc.date.accessioned 2017-10-05T16:07:53Z
dc.date.available 2017-10-05T16:07:53Z
dc.date.issued 2005
dc.identifier 10.1097/01.coc.0000145335.39398.ee
dc.identifier.isbn
dc.identifier.issn 02773732
dc.identifier.uri http://hdl.handle.net/10938/20110
dc.description.abstract Objectives: The effectiveness of cisplatinum and vinorelbine (PVn) as a salvage regimen in patients with metastatic breast cancer was reported in previous studies. This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients. Methods: Thirty-five patients were enrolled: 22 with metastatic breast carcinoma and 13 with locally advanced breast carcinoma (stage III). A total of 4 cycles of PVn were planned. After the 4th cycle, patients with metastatic breast cancer received vinorelbine biweekly until disease progression or for a total of 12 cycles, whereas those with locally advanced breast cancer who showed complete or partial response underwent curative surgery. Results: The overall response rate of our whole population was 74.29percent. For the metastatic breast cancer group, the overall response rate was 64percent, with a median survival of 19 months (range 2-36). For the locally advanced breast cancer group, the overall response rate was 92.3percent with a median time to disease progression of 26 months (range 25-27). Toxicity was acceptable, and no treatment-related mortality was encountered. Conclusions: PVn is effective as first line treatment of advanced breast cancer with overall response rate of 64percent in metastatic breast cancer and 92.3percent in locally advanced breast cancer, and acceptable toxicity. Copyright © 2005 by Lippincott Williams and Wilkins.
dc.format.extent
dc.format.extent Pages: (393-398)
dc.language English
dc.publisher PHILADELPHIA
dc.relation.ispartof Publication Name: American Journal of Clinical Oncology: Cancer Clinical Trials; Publication Year: 2005; Volume: 28; no. 4; Pages: (393-398);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC)
dc.type Review
dc.contributor.affiliation Shamseddine, A., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon, Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut 1107 2802, Lebanon
dc.contributor.affiliation Khalifeh, M., Department of Surgery, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Chehal, A., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Saliba, T., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Mourad, Y.A., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Taher, A., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Jalloul, R., Makassed General Hospital, Beirut, Lebanon
dc.contributor.affiliation Bitar, N., Sahel General Hospital, Beirut, Beirut, Lebanon
dc.contributor.affiliation Dandashi, A., Islamic Hospital, Tripoli, Lebanon
dc.contributor.affiliation Abbas, J., Department of Surgery, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Geara, F.B., Department of Radiation Oncology, American University of Beirut, Beirut, Lebanon
dc.contributor.authorAddress Shamseddine, A.; Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut 1107 2802, Lebanon; email: as04@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Surgery;
dc.contributor.authorDepartment Surgery
dc.contributor.authorDivision
dc.contributor.authorEmail as04@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Shamseddine, A
dc.contributor.authorInitials Khalifeh, M
dc.contributor.authorInitials Chehal, A
dc.contributor.authorInitials Saliba, T
dc.contributor.authorInitials Abou Mourad, Y
dc.contributor.authorInitials Taher, A
dc.contributor.authorInitials Jalloul, R
dc.contributor.authorInitials Bitar, N
dc.contributor.authorInitials Dandashi, A
dc.contributor.authorInitials Abbas, J
dc.contributor.authorInitials Geara, FB
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Shamseddine, A (reprint author), Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol Oncol, Box 113-6044, Beirut 11072802, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Acuna LR, 1999, J CLIN ONCOL, V17, P74; ANTOINE EC, 1997, P 7 INT C ANT TREAT; BERNARD A, 1998, P AN M AM SOC CLIN, V17, P491; BOTTO HG, 1998, P AN M AM SOC CLIN, V17, P498; BRUNO S, 1995, AM J CLIN ONCOL-CANC, V18, P392, DOI 10.1097-00000421-199510000-00006; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722; CHADJAA M, 1993, P AN M AM SOC CLIN, V12, P88; CROS S, 1989, SEMIN ONCOL, V16, P15; ESCUDERO P, 1998, P AN M AM SOC CLIN, V17, P529; FUMOLEAU P, 1993, J CLIN ONCOL, V11, P1245; Fumoleau P, 1997, Oncology (Williston Park), V11, P29; GARCIACONDE J, 1994, ANN ONCOL, V5, P854; GARDIN G, 1995, EUR J CANCER, V31A, P1428, DOI 10.1016-0959-8049(95)00199-S; Gunel N, 2000, TUMORI, V86, P283; HENDERSON IC, 1990, CANCER, V66, P1439, DOI 10.1002-1097-0142(19900915)66:14+1439::AID-CNCR28206614213.0.CO;2-M; HOCHSTER H, 1997, P AN M AM SOC CLIN, V16, pA173; KLASTERSKY J, 1989, J CLIN ONCOL, V7, P1087; KOLARIC K, 1983, CANCER CHEMOTH PHARM, V11, P108, DOI 10.1007-BF00254257; Kourousis C, 1998, AM J CLIN ONCOL-CANC, V21, P226, DOI 10.1097-00000421-199806000-00003; LLOMBARTCUSSAC A, 1997, P AN M AM SOC CLIN, V16, P629; Mustacchi G, 2002, ANN ONCOL, V13, P1730, DOI 10.1093-annonc-mdf290; Nagourney RA, 2000, J CLIN ONCOL, V18, P2245; Nistico C, 1999, ANN ONCOL, V10, P937, DOI 10.1023-A:1008324329562; Ray-Coquard I, 1998, CANCER, V82, P134, DOI 10.1002-(SICI)1097-0142(19980101)82:1134::AID-CNCR163.0.CO;2-3; Shamseddine AI, 1999, AM J CLIN ONCOL-CANC, V22, P298, DOI 10.1097-00000421-199906000-00018; SLEDGE GW, 1988, J CLIN ONCOL, V6, P1811; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200-JCO.20.6.1456; SMITH IE, 1995, J CLIN ONCOL, V13, P424; Sparano JA, 2000, J CLIN ONCOL, V18, P2369; Vassilomanolakis M, 2000, ANN ONCOL, V11, P1155, DOI 10.1023-A:1008377724931; WEBER BL, 1995, J CLIN ONCOL, V13, P2722
dc.description.citedCount 6
dc.description.citedTotWOSCount 5
dc.description.citedWOSCount 4
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden AJCOD
dc.identifier.pubmedID 16062082
dc.identifier.scopusID 23244462235
dc.identifier.url
dc.publisher.address 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Am. J. Clin. Oncol.-Cancer Clin. Trials
dc.relation.ispartOfIssue 4
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle American Journal of Clinical Oncology: Cancer Clinical Trials
dc.relation.ispartofPubTitleAbbr Am. J. Clin. Oncol. Cancer Clin. Trials
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 28
dc.source.ID WOS:000231080300012
dc.type.publication Journal
dc.subject.otherAuthKeyword Advanced breast cancer
dc.subject.otherAuthKeyword Cisplatinum
dc.subject.otherAuthKeyword Vinorelbine
dc.subject.otherChemCAS cisplatin, 15663-27-1, 26035-31-4, 96081-74-2
dc.subject.otherChemCAS dexamethasone, 50-02-2
dc.subject.otherChemCAS diphenhydramine, 147-24-0, 58-73-1
dc.subject.otherChemCAS doxorubicin, 23214-92-8, 25316-40-9
dc.subject.otherChemCAS gemcitabine, 103882-84-4
dc.subject.otherChemCAS metoclopramide, 12707-59-4, 2576-84-3, 364-62-5, 7232-21-5
dc.subject.otherChemCAS navelbine, 71486-22-1
dc.subject.otherChemCAS paclitaxel, 33069-62-4
dc.subject.otherChemCAS trastuzumab, 180288-69-1
dc.subject.otherChemCAS Cisplatin, 15663-27-1
dc.subject.otherChemCAS Vinblastine, 865-21-4
dc.subject.otherChemCAS vinorelbine, 71486-22-1
dc.subject.otherIndex anthracycline derivative
dc.subject.otherIndex antibiotic agent
dc.subject.otherIndex cisplatin
dc.subject.otherIndex dexamethasone
dc.subject.otherIndex diphenhydramine
dc.subject.otherIndex doxorubicin
dc.subject.otherIndex gemcitabine
dc.subject.otherIndex metoclopramide
dc.subject.otherIndex navelbine
dc.subject.otherIndex paclitaxel
dc.subject.otherIndex serotonin antagonist
dc.subject.otherIndex taxane derivative
dc.subject.otherIndex trastuzumab
dc.subject.otherIndex adult
dc.subject.otherIndex advanced cancer
dc.subject.otherIndex aged
dc.subject.otherIndex alopecia
dc.subject.otherIndex anemia
dc.subject.otherIndex bone marrow toxicity
dc.subject.otherIndex breast carcinoma
dc.subject.otherIndex cancer growth
dc.subject.otherIndex clinical article
dc.subject.otherIndex clinical trial
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex febrile neutropenia
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex metastasis
dc.subject.otherIndex nephrotoxicity
dc.subject.otherIndex neurotoxicity
dc.subject.otherIndex neutropenia
dc.subject.otherIndex phase 2 clinical trial
dc.subject.otherIndex review
dc.subject.otherIndex thrombocytopenia
dc.subject.otherIndex vomiting
dc.subject.otherIndex Adenocarcinoma
dc.subject.otherIndex Adult
dc.subject.otherIndex Aged
dc.subject.otherIndex Antineoplastic Combined Chemotherapy Protocols
dc.subject.otherIndex Bone Neoplasms
dc.subject.otherIndex Breast Neoplasms
dc.subject.otherIndex Carcinoma, Ductal
dc.subject.otherIndex Carcinoma, Lobular
dc.subject.otherIndex Cisplatin
dc.subject.otherIndex Female
dc.subject.otherIndex Follow-Up Studies
dc.subject.otherIndex Humans
dc.subject.otherIndex Liver Neoplasms
dc.subject.otherIndex Lung Neoplasms
dc.subject.otherIndex Lymphatic Metastasis
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Neoplasm Staging
dc.subject.otherIndex Pilot Projects
dc.subject.otherIndex Skin Neoplasms
dc.subject.otherIndex Survival Rate
dc.subject.otherIndex Treatment Outcome
dc.subject.otherIndex Vinblastine
dc.subject.otherKeywordPlus COLONY-STIMULATING FACTOR
dc.subject.otherKeywordPlus WEEKLY IV-VINORELBINE
dc.subject.otherKeywordPlus CANCER CHEMOTHERAPY
dc.subject.otherKeywordPlus FIRST-LINE
dc.subject.otherKeywordPlus INTRAVENOUS VINORELBINE
dc.subject.otherKeywordPlus TRIAL
dc.subject.otherKeywordPlus PACLITAXEL
dc.subject.otherKeywordPlus THERAPY
dc.subject.otherKeywordPlus REGIMEN
dc.subject.otherKeywordPlus DOCETAXEL
dc.subject.otherWOS Oncology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account